Close
Nordic 9Nordic 9

Biovance Capital Partners (investor - Venture Capital)

Portugal biovancecapital.com
See something wrong or missing? Let us know
Offices:Lisbon

Biovance Capital Partners is a biotech-focused venture capital company, investing in early-stage companies across Europe, with a focus on Spain, Portugal and Italy.

  • in 2024, Biovance Capital announced closing a first €51 million biotech fund to invest in disruptive early-stage drug development companies across Europe.
Average round investment:6.51M USD
Average number per year:1.0
Distribution: 2026 (1)
Portfolio companies: Netherlands Laigo Bio
Mostly invests in: Netherlands Netherlands (1) Health services (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Biovance Capital Partners

Name Criteria
United States Life Science Angels
73%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Thomas Würdinger
73%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Erasmus MC
73%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Netherlands Netherlands Enterprise Agency
73%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Netherlands Van Herk Ventures
73%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
France Truffle Capital
72%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.6
  • Active last 12 months: Yes
France Yaday
72%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Spain BBK
70%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Briban Invest
70%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Didier Valet
70%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Active last 12 months: Yes
Top